key: cord-0797371-tbio295u authors: Alejandro Lagunas-Rangel, Francisco; Chávez-Valencia, Venice title: What do we know about the antibody responses to SARS-CoV-2? date: 2021-01-23 journal: Immunobiology DOI: 10.1016/j.imbio.2021.152054 sha: 93ad7cd1a3ddaa8600955a6777397dcf73b0f11a doc_id: 797371 cord_uid: tbio295u Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a pandemic with millions of infected people and deaths. Currently, the scientific community is working hard to develop a specific vaccine or treatment. However, since antibody production is an important part of the adaptive immune response, to develop vaccines and therapies, we must understand the antibody response to SARS-CoV-2 infection. In this work, we summarize the most important findings of antibody-mediated immunity against SARS-CoV-2 and highlight its role in the efficient use of plasma from convalescent patients and the direct application of antibodies as treatment. 219 Recently, since plasma can not be produced on a large-scale, the use of monoclonal 220 neutralizing antibodies has also been suggested as a therapeutic and prophylactic strategy. 221 These antibodies are mainly obtained by selecting neutralizing antibodies from patients 222 infected with SARS-CoV-2 using different methodologies, although they can also be 223 designed with bioinformatic models against specific antigens, to later be cloned and induce 224 their proliferation (Cao et al., 2020) . Particularly, the use of antibodies directed against the 225 RBD region have shown good results in murine models to improve clinical characteristics 226 and even prevent infection (Cao et al., 2020; Y. Wu et al., 2020) . Furthermore, the use of a 227 neutralizing antibody directed against a conserved S1 epitope, other than RBD, has also been 228 proposed, which triggers NK-mediated antibody-dependent cellular cytotoxicity (ADCC), We want to highlight that many of the results presented in this work are preliminary, contain 242 very small patient samples, or require more trials to be conclusive. In this way, we want to 243 highlight the importance of studying antibody-mediated immunity against SARS-CoV-2 and 244 leave some questions that we hope can be answered soon: What factors intervene so that a 10 245 person does not carry out seroconversion? Is a lasting memory immunity generated after 246 infection with SARS-CoV-2? Does the transfer of antibodies from the mother prevent 247 infection of the fetus? What is the optimal time to apply the plasma of convalescent patients 248 in critically ill patients? What is the optimal concentration of neutralizing antibodies that 249 must be in the plasmas to be efficient? What precautionary strategies should be implemented against NTD and S2 is unknown the mechanism of action Notably, antibodies identified in convalescent patients showed that only those targeting the 123 RBD site with a dissociation constant (Kd) smaller or closer to that of ACE2/RBD showed 124 potent neutralization effects against pseudoviruses and true SARS-CoV-2 virions Antibodies in COVID-133 19 patients are derived from broad and diverse families of antibody heavy and light chains 134 and even in the same patient, the pattern of antibodies changed over time, only interdigitating 135 between them, suggesting that patients develop different antibodies during SARS-CoV-2 136 infection, and these are related during the early stages of the disease. IgVH 3-30 was 137 overrepresented and three clones were significantly enriched in these samples: antibodies 138 with heavy-chain variable regions belonging to the VH1-2*06, VH3-48*02, and VH3-9*01 139 families, together with the corresponding light-chain kappa (Igκ) belonging to 2-40*01/2D-140 40*01, 3-20*01, and light-chain lambda (Igλ) to 2-14*02 with the respective joining segment 141 kappa 4 (Jk4), Jk5 and joining segment lambda 1 (Jl1). This group of antibodies had a longer 142 CDR3 length than other antibodies less present in the serum and were enriched with tyrosine tendency to increase over time, while VH3-48*02, which has smallest CD3 region of these 146 three RBD IgG are mainly of the IgG1 isotype, and some patients presented the IgG3 isotype (Cao 151 In particular, for SARS-CoV-2 neutralizing antibodies, similar levels of somatic 153 hypermutation were identified, regardless of the isolation time Experiments with Rhesus monkeys showed that 159 infection with SARS-CoV-2 protects against reinfections in subsequent exposures, at least 160 for short times, where the concentration of specific antibodies produced against the virus was 161 much faster and higher in the re-exposure This presence is also mentioned in other reports, disappearing 171 28 days after delivery (Cavaliere et al., 2020). Additionally, breast milk has also shown IgG 172 and IgA antibodies against SARS-CoV-2 (Dong et al., 2020). of patients with COVID-19, treatment with the plasma of convalescent patients has 176 emerged as a therapeutic option (Figure 1B). Convalescent plasma treatment is a passive 177 administration of polyclonal antibodies to provide immediate immunity The US Food and Drug Administration (FDA) has approved 180 the use of plasma from recovered patients, which contains antibodies against the SARS-CoV-181 2, to treat critically ill people (Tanne, 2020). Currently, the effectiveness of convalescent 182 plasma is still unclear and there is insufficient data from well-controlled, adequately 8 of COVID-19. Convalescent COVID-19 patients, who recovered from moderate 185 illness, had detectable IgM and IgG levels It has been reported that plasma-187 treated patients significantly dropped the virus load within the first 12 days after transfusion 188 and improved its clinical characteristics. Gradually virus-specific IgG and IgM levels and 189 their neutralizing activities increased in patients, which remained high for more than 7 days 190 Notably, one report 201 mentions a considerable drop in antibody levels in patients who had previously seroconverted 202 60 days ago, including some patients reaching levels below the threshold for positivity. This 203 limits the use of convalescent plasma and indicates that there is a short window to collect 204 plasma from patients (Self et al., 2020) 491 Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health 492 Care Personnel in a Multistate Hospital Network -12 States Longitudinal observation and decline of neutralizing antibody 502 responses in the three months following SARS-CoV-2 infection in humans Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent 508 Plasma Covid-19: FDA approves use of convalescent plasma to treat critically 510 ill patients Collecting and evaluating convalescent plasma for COVID-19 treatment: why 513 and how? Vox Sang Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum 519 antibody responses during infection by SARS-CoV-2: an observational cohort study More people are getting COVID-19 twice, suggesting immunity wanes 522 quickly in some SARS-CoV-2 infection 526 induces robust, neutralizing antibody responses that are stable for at least three 527 months. medRxiv 1-13 532 SARS-CoV-2 infection induces sustained humoral immune responses in convalescent 533 patients following symptomatic A noncompeting pair of human 538 neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Profile of specific antibodies to SARS-CoV-2: The 541 first report 543 Systematic Comparison of Two Animal-to-Human Transmitted Human 544 Coronaviruses: SARS-CoV-2 and SARS-CoV COVID-19 antibody 547 therapeutics tracker: a global online database of antibody therapeutics for the 548 prevention and treatment of COVID-19 Treatment 551 with convalescent plasma for COVID-19 patients in Wuhan 554 Different longitudinal patterns of nucleic acid and serology testing results based on 555 disease severity of COVID-19 patients Antibodies in 558 Infants Born to Mothers With COVID-19 Pneumonia 2020. Effect 562 of Convalescent Plasma Therapy on Viral Shedding and Survival Re: Profile of 565 specific antibodies to SARS-CoV-2: The first report Treatment With Convalescent Plasma for 569 Critically Ill Patients With SARS-CoV-2 Infection Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors 573 who have recovered from COVID-19 CoV-2 in patients of novel coronavirus disease 2019 B) Proposed mechanism of antibody-585 mediated immunity during SARS-CoV-2 infection. C) Estimated time intervals and rates of 586 viral RNA, IgG, IgM and IgA in patients infected with SARS-CoV-2. The appropriate 587 interval for plasma transfusion from Because there are variations in the results of the analyzed studies, the time intervals should 589 be considered only as approximations. Question marks indicate that it is suggested but not 590 yet fully verified